ARTICLE | Clinical News

Hemispherx preclinical data

February 8, 2010 8:00 AM UTC

In a prostate specific antigen (PSA) transgenic mouse model, Ampligen significantly improved rituximab-mediated antibody-dependent cellular cytotoxicity against tumor targets and significantly enhanced PSA-specific T cell and antibody responses. The double-stranded RNA antiviral agent that activates 2-5 oligoadenylate synthetase also induced the release of proinflammatory chemokines and cytokines. Data were published in the American Journal of Obstetrics and Gynecology. Last month, Hemispherx submitted new preclinical data to FDA to address issues in a December complete response letter for Ampligen to treat chronic fatigue syndrome (CFS) (see BioCentury, Jan. 18). ...